Month: November 2022

On January 11, 2018, Amata, Emanuele; Rescifina, Antonio; Prezzavento, Orazio; Arena, Emanuela; Dichiara, Maria; Pittala, Valeria; Montilla-Garcia, Angeles; Punzo, Francesco; Merino, Pedro; Cobos, Enrique J.; Marrazzo, Agostino published an article.Recommanded Product: 39512-49-7 The title of the article was (+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties. And the article contained the following:

Methoxycarbonyl-1-phenyl-2-cyclopropylmethyl based derivatives [cis-(+)-MR200], [cis-(-)-MR201], and [trans-(±)-MR204], have been identified as new potent sigma (σ) receptor ligands. In the present paper, novel enantiomerically pure analogs were synthesized and optimized for their σ receptor affinity and selectivity. Docking studies rationalized the results obtained in the radioligand binding assay. Absolute stereochem. was unequivocally established by X-ray anal. of a precursor as camphorsulfonyl derivative The most promising compound, I, showed remarkable selectivity over a panel of more than 15 receptors as well as good chem. and enzymic stability in human plasma. An in vivo evaluation evidenced that I, in contrast to its isomers, which behave as σ1 antagonists, exhibited a σ1 agonist profile. These data clearly demonstrated that compound I, due to its σ1 agonist activity and favorable receptor selectivity and stability, provided an useful tool for the study of σ1 receptors. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Recommanded Product: 39512-49-7

The Article related to cyclopropylmethyl piperidine receptor sigma ligand neurodegenerative disorder human, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Recommanded Product: 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Filer, Crist N.; Egan, Judith A.; Nugent, Richard P. published an article in 2014, the title of the article was Synthesis and characterization of [N-methyl-3H]loperamide.Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol And the article contains the following content:

Loperamide is a piperidine butyramide mu-opiate receptor agonist and currently employed to treat diarrhea. Because a single past report of tritiating loperamide was limited to only a very low specific activity product without tech. details or extensive anal., the synthesis of [N-methyl-3H]loperamide at high specific activity was now described in detail. An imine precursor was alkylated with [3H]methyl iodide to obtain a quaternary intermediate, which was then reacted with 4-(4-chlorophenyl)-4-hydroxypiperidine to afford the desired product [N-methyl-3H]loperamide, characterized by thin layer chromatog. (TLC), HPLC, MS, UV, and proton-decoupled tritium NMR. Copyright © 2014 John Wiley & Sons, Ltd. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to tritium labeled loperamide synthesis, loperamide, mu-opiate receptor, tritium, tritium nmr, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On February 3, 2011, Ackermann, Jean; Conte, Aurelia; Hunziker, Daniel; Neidhart, Werner; Nettekoven, Matthias; Wertheimer, Stanley published a patent.HPLC of Formula: 1262988-77-1 The title of the patent was Piperidine-4-carboxamide derivatives as hormone sensitive lipase (HSL) inhibitors and their preparation and use for the treatment of diseases. And the patent contained the following:

The invention relates to piperidine-4-carboxamide derivatives of formula I, which are hormone sensitive lipase (HSL) inhibitors and which are useful in the treatment of diseases. Compounds of formula I wherein R1 is alkyl, cycloalkyl, haloalkyl, etc.; R2 is H, alkyl and cycloalkyl; R3 is (un)substituted indanyl, (un)substituted pyridinyl, (un)substituted pyrimidyl, etc.; R4 is H, alkyl and cycloalkyl; A1 is carbonyl, SO2, NHCO, etc.; A2 is O and NH and derivatives; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their HSL inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 0.04 μM. The experimental process involved the reaction of 1-Benzyl-4-hydroxypiperidine-4-carboxylic acid hydrochloride(cas: 1262988-77-1).HPLC of Formula: 1262988-77-1

The Article related to piperidinecarboxamide preparation hormone sensitive lipase hsl inhibitor treatment disease, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 1262988-77-1

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 26, 2012, Connolly, Peter J.; Bian, Haiyan; Li, Xun; Liu, Li; Macielag, Mark J.; McDonnell, Mark E. published a patent.Application of 1251006-64-0 The title of the patent was Azetidinylpiperidine derivatives as monoacylglycerol lipase inhibitors and their preparation and use for the treatment of inflammatory pain. And the patent contained the following:

The invention relates to azetidinylpiperidine of formula I, which are monoacylglycerol lipase (MGL) inhibitors and which are useful in the treatment of inflammatory pain. Compounds of formula I wherein Y and Z are independently (un)substituted C6-10 aryl, (un)substituted thiazolyl, (un)substituted isothiazolyl, etc.; R is H and OH; with provisions; and enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their MGL inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 0.006 μM. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Application of 1251006-64-0

The Article related to azetidinyl piperidine preparation monoacylglycerol lipase inhibitor treatment inflammatory pain, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Application of 1251006-64-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On June 23, 2016, Bradner, James; Buckley, Dennis; Winter, Georg published a patent.Computed Properties of 1216805-11-6 The title of the patent was Methods to induce targeted protein degradation through bifunctional molecules. And the patent contained the following:

The present application provides bifunctional compounds I [wherein: M = (R1)m; Y is a bond, (CH2)1-6, (CH2)0-6-O, (CH2)0-6-C(:O)NR2′, (CH2)0-6-NR2’C(:O), (CH2)0-6-NH or (CH2)0-6-NR2; X is C(:O) or C(R3)2;]. [Each R1 is independently halogen, OH, C1-6-alkyl or C1-6-alkoxy; R2 is C1-6-alkyl, C(:O)-C1-6-alkyl or C(:O)-C3-6-cycloalkyl; R2′ is H or C1-6-alkyl; each R3 is independently H or C1-3-alkyl; each R3′ is independently C1-3-alkyl;]. [Each R4is independently H or C1-3-alkyl and at least one R4 is C1-3-alkyl; or two R4, together with the carbon atom to which they are attached, form a C3-6-carbocycle or a 4-, 5- or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from N and O;]. [R5 is H, deuterium, C1-3-alkyl, F or Cl; ; m is 0, 1, 2 or 3; n is 0, 1 or 2; the Linker is a group that covalently binds to the Targeting Ligand and Y; and, the Targeting Ligand binds to a targeted protein selected from EGFR, FLT3, KSR1, Raf, SMARCA2 and Ras] and II [ X1-X2 is C(R3):N or C(R3)2-C(R3)2;], or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof. Thus, dBET1 [DB-2-190-2 (III)] was prepared from JQ1 (IV) via acid hydrolysis with HCO2H and amidation with N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide trifluoroacetate (V·CF3CO2H) in DMF containing HATU and DIPEA. The bioactivity of III was determined [IC50 = 20 nM vs. BRD4; 85% loss of BRD4 in a human AML cell line MV4-11 an 100 nM; potent downregulation of total BRD4 in human cancer cell line SUM149 breast cancer cells (EC50 = 430 nM); showed comparable response in cell lines SUM159 and MOLM13]. The experimental process involved the reaction of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid(cas: 1216805-11-6).Computed Properties of 1216805-11-6

The Article related to steroid bifunctional derivative preparation induction targeted protein degradation, proliferative disorder treatment steroid bifunctional derivative, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Computed Properties of 1216805-11-6

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Ronson, Thomas O.; Renders, Evelien; Van Steijvoort, Ben F.; Wang, Xubin; Wybon, Clarence C. D.; Prokopcova, Hana; Meerpoel, Lieven; Maes, Bert U. W. published an article in 2019, the title of the article was Ruthenium-Catalyzed Reductive Arylation of N-(2-Pyridinyl)amides with Isopropanol and Arylboronate Esters.Quality Control of 4-(4-Chlorophenyl)piperidin-4-ol And the article contains the following content:

A new three-component reductive arylation of amides with stable reactants (iPrOH and arylboronate esters), making use of a 2-pyridinyl (Py) directing group, is described. The N-Py-amide substrates are readily prepared from carboxylic acids and PyNH2, and the resulting N-Py-1-arylalkanamine reaction products are easily transformed into the corresponding chlorides by substitution of the HN-Py group with HCl. The 1-aryl-1-chloroalkane products allow substitution and cross-coupling reactions. Therefore, a general protocol for the transformation of carboxylic acids into a variety of functionalities is obtained. The Py-NH2 byproduct can be recycled. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Quality Control of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to multicomponent reductive arylation amide arylboronate ester pyridinyl directing group, amides, amines, arylation, multicomponent reactions, ruthenium, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Quality Control of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On May 31, 2018, Gray, Nathanael S.; Dobrovolsky, Dennis; Huang, Hai-Tsang published a patent.COA of Formula: C14H10N2O6 The title of the patent was Degradation of Bruton’s tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use. And the patent contained the following:

The present invention provides bifunctional compounds Targeting Ligand-Linker-Degron [I; the Targeting Ligand (TL) is capable of binding to one or more protein kinases (TL = II [B = (un)substituted Ph or 5-6 membered heteroaryl containing 1-2 heteroatoms selected from N, S; when Y1 is absent, B is bonded to a carbon atom or Y4 in III; Y1 = absent or C(O), wherein Y1 is bonded to a carbon atom or Y4 in III; Y2 = O or NR10a; Y3 = C(O)NR10b or NR10bC(O); Y4 = NR51 or, when Y1 is bonded to Y4 or when Y1 is absent and B is bonded to Y4, Y4 = N (wherein R51 = H, alkyl, haloalkyl, etc.); each R5 = alkyl, haloalkyl, alkoxy, etc.; R6 = H, alkyl, haloalkyl; each R7 = alkyl, haloalkyl, alkoxy, etc.; each R8 = alkyl, haloalkyl, alkoxy, etc.; R9 = alkyl, haloalkyl, alkoxy, etc.; R10a and R10b = H, alkyl or haloalkyl; o1, o2 or o3 = 0-3], etc.); the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase] or enantiomers, diastereomers, or stereoisomers thereof, or pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof, which act as protein degradation inducing moieties for Bruton’s tyrosine kinase (BTK). Compound IV was prepared in a multi-step synthesis, starting from tert-Bu piperazine-1-carboxylate and 4-nitrobenzoic acid. The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds I that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK. Exemplified compound IV was tested and showed BTK degradation in the cell assay. Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid(cas: 1216805-11-6).COA of Formula: C14H10N2O6

The Article related to bifunctional compound preparation protein btk degradation inducer ubiquitin ligase, antitumor bifunctional compound preparation bruton’s tyrosine kinase btk inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.COA of Formula: C14H10N2O6

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On May 31, 2018, Bradner, James; Buckley, Dennis; Ishoey, Mette; Winter, Georg published a patent.Name: 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid The title of the patent was Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use. And the patent contained the following:

The present invention provides bifunctional compounds Targeting Ligand-Linker-Degron [I; the Targeting Ligand (TL) is capable of binding to one or more protein kinases (TL = II [X1 = NR5 or O; each R1 and each R4 = (independently) alkyl, haloalkyl, alkoxy, etc.; R2 and R3 = (independently) H, alkyl, or haloalkyl; R5 = H, alkyl, haloalkyl, or C(O)alkyl; n1 = 0-3; n2 = 0-2], III [A = (un)substituted aryl or 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, S, and O; X2 = O, S, or NR10; X3 = N or CR11; each R6 = (independently) alkyl, haloalkyl, alkoxy, etc.; R7 = H, alkyl, or haloalkyl; each R8 and each R9 = (independently) alkyl, haloalkyl, alkoxy, etc.; R10 = H or alkyl; R11 = alkyl, haloalkyl, alkoxy, etc.; q1 = 0-4; q2 = 0-3], etc.); the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase] or enantiomers, diastereomers, or stereoisomers thereof, or pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof, which act as protein degradation inducing moieties for protein kinases. Fifteen compounds I [TL = II] were prepared Thus, amidating N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide with Sunitinib acid afforded 36% IV. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds I that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases. Exemplified compounds I were tested in the dose-ranging viability assays (data given for representative compounds I). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid(cas: 1216805-11-6).Name: 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid

The Article related to bifunctional compound preparation protein degradation inducer ubiquitin ligase binding, antitumor bifunctional compound preparation e3 ubiquitin ligase binding moiety, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Name: 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On August 31, 2014, Shimakami, Natsumi; Yabutani, Tomoki; Takayanagi, Toshio published an article.Name: 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was Analysis of acid dissociation of photo-degradable haloperidol through the measurement of electrophoretic mobility by capillary zone electrophoresis. And the article contained the following:

The acid dissociation constants (Ka) of Haloperidol and its degraded product were determined by capillary zone electrophoresis (CZE). Haloperidol is degraded by UV-light irradiation, and 4-(p-chlorophenyl)-4-hydroxypiperidine (CPHP) is generated from Haloperidol. When the irradiated solution was analyzed by CZE, residual Haloperidol and two degraded products were detected. The acid dissociation constant of Haloperidol was determined through the electrophoretic mobility of the residual Haloperidol, and the pKa value determined was similar to that measured under no degradation conditions, as well as literature values. It was also confirmed that one of the degraded products was assigned to CPHP based on the migration time, the electrophoretic mobility, and its acid dissociation constant analyzed. It was demonstrated in this study that the acid dissociation constants are accurately determined by using CZE, even under degraded conditions of the analyte. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Name: 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to haloperidol photodegradation acid dissociation constant capillary zone electrophoresis, Pharmaceutical Analysis: Synthetic Organic Compounds and other aspects.Name: 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Gitto, Rosaria; De Luca, Laura; Mancuso, Francesca; Del Prete, Sonia; Vullo, Daniela; Supuran, Claudiu T.; Capasso, Clemente published an article in 2019, the title of the article was Seeking new approach for therapeutic treatment of cholera disease via inhibition of bacterial carbonic anhydrases: experimental and theoretical studies for sixteen benzenesulfonamide derivatives.Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol And the article contains the following content:

A series of sixteen benzenesulfonamide derivatives has been synthesized and tested as inhibitors of Vibrio cholerae carbonic anhydrase (CA) enzymes, belonging to α-CA, β-CA, and γ-CA classes (VchCAα, VchCAβ, and VchCAγ). The determined Ki values were compared to those of selected human CA isoforms (hCA I and hCA II). Structure-affinity relationship anal. highlighted that all tested compounds proved to be active inhibitors of VchCAα at nanomolar concentration The VchCAβ activity was lower to respect inhibitory efficacy toward VchCAα, whereas, these benzenesulfonamide derivatives failed to inhibit VchCAγ. Interestingly, compound combined the best activity toward VchCAα and VchCAβ. In order to obtain a model for binding mode of our inhibitors toward bacterial CAs, we carried out docking simulations by using the available crystal structures of VchCAβ. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to benzene sulfonamide derivative preparation carbonic anhydrase inhibitor cholera, carbonic anhydrase inhibitors (cais), benzenesulfonamides, molecular docking, Pharmacology: Effects Of Antimicrobials and Parasiticides and other aspects.Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem